Economic Impact Analysis

Expanding access to high-quality, affordable health care has been a priority of the Biden-Harris Administration.

The U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Planning and Evaluation (ASPE) released new research on spending and utilization trends of Medicare Part B drugs, drugs administered in physicians' office or hospital outpatient departments rather than being purchased at the pharmacy counter or by mail order.

This study updates ASPE’s previous analysis of the associations between COVID-19 hospitalizations and deaths among Medicare beneficiaries and COVID-19 vaccination rates, with full year data through the end of 2021.

This posting includes a report prepared by the RAND Corporation, “State All Payer Claims Databases Understanding the Current Landscape and Challenges to Use,” which builds on a 2021 report “The History, Promise and Challenges of State All Payer Claims Databases.” The new report provides additional detail on the objectives of and use cases for APCDs, the current APCD landscape, and implementati

This report develops an approach for valuing COVID-19 mortality and morbidity risk reductions based on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. Valuing risk reductions associated with regulations or other policies that address the novel coronavirus disease 2019 (COVID-19) presents major challenges.

The purpose of this study is to describe and document changes states have made to their Medicaid or other publicly-funded consumer directed home care programs for seniors and individuals with disabilities to comply with the 2013 update to Fair Labor Standards Act (FLSA) regulations.

There are multiple pathways to becoming dually eligible for Medicare and Medicaid. The purpose of this study is to identify the frequency with which these pathways are followed and the beneficiary characteristics and patterns of service use by pathway.

The U.S. Department of Health and Human Services (HHS) is required to assess the benefits and costs of its major regulations prior to promulgation. To support these assessments, in 2016 HHS issued its Guidelines for Regulatory Impact Analyses, developed under the leadership of its Office of the Assistant Secretary for Planning and Evaluation and its Department-wide Analytics Team.